Half-dose rivaroxaban vs antiplatelet therapy for preventing silent cerebral embolic lesions after left atrial appendage occlusion: the HALO-SCE trial

拜瑞妥 医学 抗血栓 内科学 心脏病学 心房颤动 随机对照试验 栓塞 入射(几何) 麻醉 华法林 置信区间 左心耳阻塞 冲程(发动机) 磁共振成像 血小板聚集抑制剂 血栓形成 抗血小板药物 血栓栓塞性中风 认知 临床试验 蒙特利尔认知评估 心耳 外科 睡眠剥夺对认知功能的影响 认知功能衰退
作者
Kexin Wang,Linsheng Shi,Zhongbao Ruan,Hongwu Chen,Hailei Liu,Zidun Wang,Xiaohong Jiang,Mingfang Li,Minglong Chen,Weizhu Ju
出处
期刊:European Heart Journal [Oxford University Press]
标识
DOI:10.1093/eurheartj/ehag734
摘要

BACKGROUND AND AIMS: The optimal long-term antithrombotic strategy after left atrial appendage occlusion (LAAO) remains undetermined. The present study aimed to investigate whether half-dose rivaroxaban (10 mg daily) could better reduce silent cerebral embolic lesions (SCEs) and preserve cognitive function compared to antiplatelet therapy after successful LAAO. METHODS: In this investigator-initiated, prospective, multicenter, randomized controlled trial, patients with successful LAAO confirmed 45 days post-procedure were assigned 1:1 to half-dose rivaroxaban or antiplatelet therapy group. Diffusion-weighted magnetic resonance imaging and cognitive assessments were repeated at 90, 180 and 365 days after LAAO. The primary outcome was the patient-level incidence of any newly detected SCE during follow-up. Secondary outcomes included cognitive trajectories, SCE burden, and a composite of all-cause mortality, clinical thromboembolic events and major bleeding. RESULTS: Between December 2022 and February 2025, 164 patients were randomized. The patient-level incidence of new SCEs was significantly lower in the half-dose rivaroxaban group than in the antiplatelet therapy group (10/82 [12.2%] vs. 26/82 [31.7%]; P = 0.005). At 365 days, model-derived between-group differences favored the half-dose rivaroxaban group for both Mini-Mental State Examination (2.56; 95% confidence interval [CI] 1.11-4.01; P < 0.001) and Montreal Cognitive Assessment (2.67; 95% CI 1.07-4.26; P = 0.001) scores. The composite clinical outcome occurred in 2.4% of the half-dose rivaroxaban group vs. 11.0% of the antiplatelet therapy group (P = 0.057). CONCLUSIONS: In patients eligible for oral anticoagulation after successful LAAO, rivaroxaban 10 mg daily significantly reduced SCEs and better maintained cognitive function compared with antiplatelet therapy, with numerically fewer composite clinical events.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
酷波er的应助被n11采纳,获得10
刚刚
1秒前
搜集达人的应助被AoAoo采纳,获得10
2秒前
easynature完成签到 ,获得积分20
2秒前
372721759发布了新的文献求助30
2秒前
cdercder的应助被TinTin采纳,获得10
3秒前
风趣小松鼠完成签到,获得积分10
3秒前
科研通AI2S的应助被Lu采纳,获得10
3秒前
Plus是只喵完成签到,获得积分20
3秒前
3秒前
4秒前
洁净盛男发布了新的文献求助30
5秒前
所所的应助被奇异果采纳,获得10
5秒前
6秒前
怕黑的飞柏完成签到 ,获得积分10
6秒前
lllllll完成签到 ,获得积分10
7秒前
7秒前
田様的应助被ynuxb采纳,获得10
7秒前
7秒前
aaa关闭了aaa的文献求助
8秒前
新新完成签到 ,获得积分20
8秒前
Nichols完成签到,获得积分0
8秒前
wty完成签到,获得积分10
8秒前
辛未发布了新的文献求助10
9秒前
科研通AI6.4的应助被TINASO采纳,获得10
9秒前
9秒前
小川完成签到,获得积分10
9秒前
张y发布了新的文献求助10
10秒前
10秒前
10秒前
Zhangyuanjie发布了新的文献求助10
11秒前
安安发布了新的文献求助30
11秒前
11秒前
12秒前
喵喵轩完成签到,获得积分10
12秒前
13秒前
n11发布了新的文献求助10
13秒前
威武的海棠花完成签到,获得积分10
13秒前
13秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183204
求助须知:如何正确求助?哪些是违规求助? 9572482
关于积分的说明 21825940
捐赠科研通 7780074
什么是DOI,文献DOI怎么找? 3433945
关于科研通互助平台的介绍 2558060
邀请新用户注册赠送积分活动 2480166